Source 1primary paper2025MED
Toolkit/isoform-selective antibody or CAR-T designs
isoform-selective antibody or CAR-T designs
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Emerging therapeutic strategies aim to counteract these processes through antisense oligonucleotide-mediated splicing correction, pharmacologic modulation of splicing regulators, and isoform-selective antibody or CAR-T designs.
Usefulness & Problems
Why this is useful
These designs aim to selectively recognize therapeutically relevant antigen isoforms shaped by alternative splicing. The abstract frames them as a way to overcome splicing-driven immune escape.; targeting resistance-associated antigen isoforms; designing RNA-informed precision antibody therapies
Source:
These designs aim to selectively recognize therapeutically relevant antigen isoforms shaped by alternative splicing. The abstract frames them as a way to overcome splicing-driven immune escape.
Source:
targeting resistance-associated antigen isoforms
Source:
designing RNA-informed precision antibody therapies
Problem solved
They are intended to address antigenic diversity created by alternative splicing that undermines standard antibody-based therapies. The goal is to preserve target recognition despite isoform remodeling.; immune escape caused by splicing-generated antigen isoforms
Source:
They are intended to address antigenic diversity created by alternative splicing that undermines standard antibody-based therapies. The goal is to preserve target recognition despite isoform remodeling.
Source:
immune escape caused by splicing-generated antigen isoforms
Problem links
immune escape caused by splicing-generated antigen isoforms
LiteratureThey are intended to address antigenic diversity created by alternative splicing that undermines standard antibody-based therapies. The goal is to preserve target recognition despite isoform remodeling.
Source:
They are intended to address antigenic diversity created by alternative splicing that undermines standard antibody-based therapies. The goal is to preserve target recognition despite isoform remodeling.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
isoform-selective antigen recognitionTechniques
Computational DesignTarget processes
No target processes tagged yet.
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: actuator
They require antibody or CAR-T engineering informed by isoform structure and expression. The abstract does not specify any particular construct or targeting epitope.; requires knowledge of therapeutically relevant isoforms and compatible antibody or CAR-T targeting designs
The abstract does not show that isoform-selective designs solve all forms of tumor heterogeneity or non-antigen-based resistance. It also does not provide evidence for clinical performance.; the abstract does not specify design rules, validated constructs, or comparative performance
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Aberrant activity of splicing regulators disrupts canonical exon selection, leading to altered receptor signaling or secretion of soluble decoy isoforms that evade immune recognition.
Emerging strategies to counteract splicing-mediated resistance include antisense oligonucleotide-mediated splicing correction, pharmacologic modulation of splicing regulators, and isoform-selective antibody or CAR-T designs.
Understanding splicing-driven antigenic plasticity provides a framework for RNA-informed precision antibody therapies designed to restore antigen expression, overcome immune escape, and enhance durable clinical responses.
Approval Evidence
1 source2 linked approval claimsfirst-pass slug isoform-selective-antibody-or-car-t-designs
Emerging therapeutic strategies aim to counteract these processes through antisense oligonucleotide-mediated splicing correction, pharmacologic modulation of splicing regulators, and isoform-selective antibody or CAR-T designs.
Source:
therapeutic strategysupports
Emerging strategies to counteract splicing-mediated resistance include antisense oligonucleotide-mediated splicing correction, pharmacologic modulation of splicing regulators, and isoform-selective antibody or CAR-T designs.
Source:
translational frameworksupports
Understanding splicing-driven antigenic plasticity provides a framework for RNA-informed precision antibody therapies designed to restore antigen expression, overcome immune escape, and enhance durable clinical responses.
Source:
Comparisons
Source-stated alternatives
The abstract lists antisense oligonucleotide-mediated splicing correction and pharmacologic modulation of splicing regulators as alternative intervention strategies.
Source:
The abstract lists antisense oligonucleotide-mediated splicing correction and pharmacologic modulation of splicing regulators as alternative intervention strategies.
Source-backed strengths
explicitly adapts targeting strategy to isoform-level antigen diversity
Source:
explicitly adapts targeting strategy to isoform-level antigen diversity
Compared with antisense oligonucleotide
The abstract lists antisense oligonucleotide-mediated splicing correction and pharmacologic modulation of splicing regulators as alternative intervention strategies.
Shared frame: source-stated alternative in extracted literature
Strengths here: explicitly adapts targeting strategy to isoform-level antigen diversity.
Relative tradeoffs: the abstract does not specify design rules, validated constructs, or comparative performance.
Source:
The abstract lists antisense oligonucleotide-mediated splicing correction and pharmacologic modulation of splicing regulators as alternative intervention strategies.
Compared with antisense oligonucleotide-mediated splicing correction
The abstract lists antisense oligonucleotide-mediated splicing correction and pharmacologic modulation of splicing regulators as alternative intervention strategies.
Shared frame: source-stated alternative in extracted literature
Strengths here: explicitly adapts targeting strategy to isoform-level antigen diversity.
Relative tradeoffs: the abstract does not specify design rules, validated constructs, or comparative performance.
Source:
The abstract lists antisense oligonucleotide-mediated splicing correction and pharmacologic modulation of splicing regulators as alternative intervention strategies.
Ranked Citations
- 1.